SCHEMBL696000

SCHEMBL696000

COc1cccc(Cl)c1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.74
CA1 P00915 1/20 0.74
CA2 P00918 1/20 0.74
CA7 P43166 1/20 0.74
CA9 Q16790 1/20 0.74
CA14 Q9ULX7 1/20 0.74
FABP4 P15090 1/20 0.58
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PPARA Q07869 1/20 0.50
RORC P51449 1/20 0.47
CXCL12 P48061 1/20 0.46
HTT P42858 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
DPP4 P27487 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2,6-Dimethoxybenzoic Acid SCHEMBL149926 0.86 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL24301693 0.85 CA9 (0.57) CA12CA1CA2CA7CA9
SCHEMBL1622269 0.85 ALDH1A1 (0.63) CA12CA1CA2CA7CA9
SCHEMBL28312260 0.84 CA12 (0.56) CA12CA1CA2CA7CA9
2,6-Dimethoxybenzoic Acid SCHEMBL28906099 0.84 CA12 (0.95) CA12CA1CA2CA7CA9
2,6-Dimethoxybenzoic Acid SCHEMBL11457745 0.84 CA12 (0.95) CA12CA1CA2CA7CA9
2,6-Dimethoxybenzoic Acid SCHEMBL28252005 0.84 CA12 (0.95) CA12CA1CA2CA7CA9
2,6-Dimethoxybenzoic Acid SCHEMBL7867072 0.84 CA12 (0.95) CA12CA1CA2CA7CA9
2,6-Dimethoxybenzoic Acid SCHEMBL10830715 0.84 CA12 (0.95) CA12CA1CA2CA7CA9
SCHEMBL9713219 0.83 CA12 (0.55) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101511175-A Alkoxylated alkylamines or alkoxylated alkyl ether amines with peaked distribution AKZO NOBEL NV (NL) 2009-08-19 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION FIBROGEN, INC. 2024-01-04 US disclosed
US-20230381146-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF HELIOS HUAMING BIOPHARMA CO., LTD. (CN) 2023-11-30 US disclosed
US-20230381146-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF HELIOS HUAMING BIOPHARMA CO., LTD. (CN) 2023-11-30 US disclosed
US-20230381146-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF HELIOS HUAMING BIOPHARMA CO., LTD. (CN) 2023-11-30 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
EP-4225743-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF Helios Huaming Biopharma Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-1676832-A2 Compounds and compositions for delivering active agents Emisphere Technologies, Inc. (US) 2006-07-05 EP disclosed
US-6991798-B1 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2006-01-31 US disclosed
US-20050272638-A1 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2005-12-08 US disclosed
CN-1441790-A Enhanced propertied pharmaceuticals ROHM & HAAS (US) 2003-09-10 CN disclosed
EP-1102742-A2 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2001-05-30 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000007979-A2 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2000-02-17 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
EP-0863881-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-09-16 EP disclosed
WO-1997010219-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272638-A1 Compounds and compositions for delivering active agents SERPINB1, ELANE, MMP8 CA12 469/4885CA1 1393/4885CA2 3245/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CA12 3802/4885CA1 2762/4885CA2 2217/4885
US-20230381146-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF SSB, BTK, PADI6 CA12 3394/4885CA1 3828/4885CA2 3562/4885
US-20240002344-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION KDM5C, KDM5B, KDM5A CA12 3916/4885CA1 3189/4885CA2 2638/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP CA12 4341/4885CA1 4396/4885CA2 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.